Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer’s Disease And …

Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer’s Disease And Migraine ProgramsDetails Category: More News Published on Wednesday, 02 September 2015 10:11 Hits: 60 Global Co-Development and Co-Commercialization Agreement in Alzheimer’s Disease With Novartis’ Phase 1/2a BACE Inhibitor as the Lead Preventative Treatment Approach Directed at Genetically Predisposed Individuals at Risk of Developing Alzheimer’s Disease; Builds on Amgen’s Genetic Validation Strategy Global Co-Development Agreement More Rapidly Advances Amgen’s Migraine Programs, Including AMG 334 in Phase 3 Amgen Retains Migraine Commercialization Rights in the U.S., Japan and Canada; Provides Novartis With Rights to Commercialize Migraine Programs in Europe and Rest of World; Leverages Novartis’ Strong Commercial Neuroscience Presence THOUSAND OAKS, CA, USA I Sept. 1, 2015 I Amgen (NASDAQ:AMGN) today announced a neuroscience collaboration with Novartis in the areas of…


Link to Full Article: Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer’s Disease And …

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!